Cargando…

SARS-CoV-2 variants and considerations of inferring causality on disease severity

Detalles Bibliográficos
Autores principales:	Cevik, Muge, Mishra, Sharmistha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219487/ https://www.ncbi.nlm.nih.gov/pubmed/34171234 http://dx.doi.org/10.1016/S1473-3099(21)00338-8

Ejemplares similares

Immunological considerations for SARS-CoV-2 human challenge studies
por: Douglas, Alexander D., et al.
Publicado: (2020)

Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity
por: Markov, Peter V., et al.
Publicado: (2022)

Decoding the next SARS-CoV-2 variant
por: Nel, Jeremy, et al.
Publicado: (2022)

Importance of epidemiological factors in the evaluation of transmissibility and clinical severity of SARS-CoV-2 variants
por: Lechien, Jérôme R, et al.
Publicado: (2022)

Estimating disease severity of Omicron and Delta SARS-CoV-2 infections
por: Sigal, Alex, et al.
Publicado: (2022)

SARS-CoV-2 variants and ending the COVID-19 pandemic
por: Fontanet, Arnaud, et al.
Publicado: (2021)

Will SARS-CoV-2 variants of concern affect the promise of vaccines?
por: Gupta, Ravindra K.
Publicado: (2021)

Managing waning vaccine protection against SARS-CoV-2 variants
por: Leung, Kathy, et al.
Publicado: (2022)

Recalling ancestral SARS-CoV-2 variants: is it an original sin with benefits?
por: Hoehl, Sebastian, et al.
Publicado: (2023)

SARS-CoV-2 testing for public health use: core principles and considerations for defined use settings
por: Boehme, Catharina, et al.
Publicado: (2021)

Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era
por: Wang, Stephen Y, et al.
Publicado: (2022)

SARS-CoV-2 delta variant: a persistent threat to the effectiveness of vaccines
por: Thiruvengadam, Ramachandran, et al.
Publicado: (2022)

Travel measures in the SARS-CoV-2 variant era need clear objectives
por: Kucharski, Adam J, et al.
Publicado: (2022)

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies
por: Nadesalingam, Angalee, et al.
Publicado: (2023)

COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants
por: Cevik, Muge, et al.
Publicado: (2021)

What is the vaccine effect on reducing transmission in the context of the SARS-CoV-2 delta variant?
por: Wilder-Smith, Annelies
Publicado: (2022)

Understanding how fast SARS-CoV-2 variants transmit from household studies
por: Yang, Yang, et al.
Publicado: (2022)

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
por: Karim, Salim S Abdool, et al.
Publicado: (2021)

Neutralizing antibodies and their cocktails against SARS-CoV-2 Omicron and other circulating variants
por: Yang, Yang, et al.
Publicado: (2022)

SARS-CoV-2 variants offer a second chance to fix vaccine inequities
por: Hotez, Peter J.
Publicado: (2022)

SARS-CoV-2 severity in African Americans – a role for Duffy null?
por: Hebbel, Robert P., et al.
Publicado: (2020)

Global emergence of SARS-CoV-2 variants: new foresight needed for improved vaccine efficacy
por: Yadav, Pragya D, et al.
Publicado: (2022)

SARS-CoV-2 Lambda and Gamma variants competition in Peru, a country with high seroprevalence
por: Vargas-Herrera, Natalia, et al.
Publicado: (2021)

Asymptomatic SARS-CoV-2 infection
por: Ooi, Eng Eong, et al.
Publicado: (2020)

The complexities of SARS-CoV-2 serology
por: Houlihan, Catherine F, et al.
Publicado: (2020)

Neonatal SARS-CoV-2 infection
por: de Carvalho, Werther Brunow, et al.
Publicado: (2020)

Towards SARS-CoV-2 serotypes?
por: Simon-Loriere, Etienne, et al.
Publicado: (2022)

Monitoring differences between the SARS-CoV-2 B.1.1.7 variant and other lineages
por: Jewell, Britta L
Publicado: (2021)

New year, new SARS-CoV-2 variant: Resolutions on genomic surveillance protocols to face Omicron
por: Oróstica, Karen Y., et al.
Publicado: (2022)

Public health actions to control new SARS-CoV-2 variants
por: Grubaugh, Nathan D., et al.
Publicado: (2021)

Pre-exposure anti-SARS-CoV-2 monoclonal antibodies in severely immunocompromised patients with immune-mediated inflammatory diseases
por: Goulenok, Tiphaine, et al.
Publicado: (2022)

Bell's palsy and SARS-CoV-2 vaccines
por: Ozonoff, Al, et al.
Publicado: (2021)

Understanding the drivers of transmission of SARS-CoV-2
por: Cornelissen, Laura, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in people with HIV
por: Spinelli, Matthew A
Publicado: (2021)

Optimising SARS-CoV-2 vaccination schedules
por: Belda-Iniesta, Cristobal
Publicado: (2021)

The SARS-CoV2 pandemic and routine immunisation
por: Kang, Gagandeep
Publicado: (2022)

Sustainability of surveillance systems for SARS-CoV-2
por: Adlhoch, Cornelia, et al.
Publicado: (2022)

Immunosuppression and SARS-CoV-2 breakthrough infections
por: Kim, Alfred H J, et al.
Publicado: (2022)

Antibodies, epicenter of SARS-CoV-2 immunology
por: Pecetta, Simone, et al.
Publicado: (2021)

Diabetes after SARS-CoV-2 infection
por: Al-Aly, Ziyad
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mtkmbnuq0h6vvinr8hotdnq0sa